Successful multifold dose escalation of anti-G D2 monoclonal antibody 3F8 in patients with neuroblastoma: A phase I study Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Bone Marrow Neoplasms
  • Bone Neoplasms
  • Gangliosides
  • Immunotherapy
  • Neuroblastoma

abstract

  • Multifold dose escalation of 3F8 is feasible. The findings can be interpreted as compatible with the possibility that HM3F8 can modify toxicity without blunting anti-NB activity. This pain control strategy may help achieve dose escalation with other anti-G(D2) MoAbs.

publication date

  • March 20, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3083872

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.28.3317

PubMed ID

  • 21343563

Additional Document Info

start page

  • 1168

end page

  • 74

volume

  • 29

number

  • 9